In a syngeneic mouse model of SM1 BRAFV600E mutant melanoma, triplet therapy demonstrated heightened anti-tumour activity compared with either anti-PD-1 monotherapy or anti-PD-1 in combination with either BRAFi or MEKi alone [26, 27]. This evidence concerns the gene PDCD1 and melanoma.